{"denoms":[{"counts":[{"groupId":"BG000","value":"24"}],"units":"Participants"}],"groups":[{"description":"cis 75 mg/m2 (SOC), doce 74 mg/m2 (SOC), pembro 200mg (Exp), Q3W IV","id":"BG000","title":"Experimental (Cis/Doce/Pembro)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"12"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"19"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"20"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Smoking >/= 10 App : No"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"Smoking >/= 10 App : Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Alcohol: Heavy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"Alcohol: Moderate"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Alcohol: Light"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"ECOG Status: 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"ECOG Status: 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Primary Site: Glottic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Primary Site: Supraglottic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"Stage at treatment: II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"Stage at treatment: III"}],"description":"ECOG (Eastern Cooperative Oncology Group) Performance status is a 0-5 scale to measure cancer patients' level of functioning and ability to perform daily activities. 0 = fully active w/ no performance restrictions. 1 = restricted in physically strenuous activity but ambulatory, can perform light work. The American Joint Committee on Cancer (AJCC) 7th edition cancer staging guidelines evaluates the T (Tumor), N (Nodes), and M (Metastasis) components of the primary cancer and assigns stage grouping (stages 0-IV). Stages II/III are locally advanced, with stage III being more severe.","paramType":"COUNT_OF_PARTICIPANTS","title":"Distribution of categorical clinical characteristics among evaluable participants","unitOfMeasure":"Participants"}]}